RIGEL PHARMACEUTICALS INC (RIGL)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 35M 70M 105M Q3 '21: 21.5M Q4 '21: 20.4M Q1 '22: 16.7M Q2 '22: 29.8M Q3 '22: 22.4M Q4 '22: 51.3M Q1 '23: 26.1M Q2 '23: 26.9M Q3 '23: 28.1M Q4 '23: 35.8M Q1 '24: 29.5M Q2 '24: 36.8M Q3 '24: 55.3M Q4 '24: 57.6M Q1 '25: 53.3M Q2 '25: 101.7M Q3 '25: 69.5M Q4 '25: 69.8M Q1 '26: 58.8M Q2 '26: 78.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit Quarterly

0 6M 12M 18M Q2 '18: 1.8M Q3 '18: 4.8M Q4 '18: 7.1M Q1 '19: 7.9M Q2 '19: 9.9M Q3 '19: 11.4M Q4 '19: 13.7M Q1 '20: 12.5M Q2 '20: 14.7M Q3 '20: 16.1M Q4 '20: 17.4M Q2 '18 Q4 '18 Q2 '19 Q4 '19 Q2 '20 Q4 '20

Operating Income Quarterly

-50M -25M 0 25M 50M 75M Q3 '21: -19.8M Q4 '21: -21.4M Q1 '22: -26.3M Q2 '22: -13M Q3 '22: -18.4M Q4 '22: 2.1M Q1 '23: -12.7M Q2 '23: -5.3M Q3 '23: -4.5M Q4 '23: 2M Q1 '24: -7M Q2 '24: 447K Q3 '24: 14.1M Q4 '24: 16.7M Q1 '25: 12.8M Q2 '25: 61.1M Q3 '25: 28.4M Q4 '25: 23.2M Q1 '26: 11.9M Q2 '26: 23.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-100M 0 100M 200M 300M Q3 '21: -21M Q4 '21: -22.6M Q1 '22: -27.4M Q2 '22: -13.5M Q3 '22: -19M Q4 '22: 1.4M Q1 '23: -13.5M Q2 '23: -6.6M Q3 '23: -5.7M Q4 '23: 737K Q1 '24: -8.2M Q2 '24: -1M Q3 '24: 12.4M Q4 '24: 14.3M Q1 '25: 11.4M Q2 '25: 59.6M Q3 '25: 27.9M Q4 '25: 268.1M Q1 '26: 8.7M Q2 '26: 17.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 3M 6M 9M Q3 '21: 151K Q4 '21: 487K Q1 '22: 121K Q2 '22: 1M Q3 '22: 250K Q4 '22: 342K Q1 '23: 977K Q2 '23: 1.1M Q3 '23: 1.3M Q4 '23: 3.8M Q1 '24: 2M Q2 '24: 2.8M Q3 '24: 8M Q4 '24: 5.8M Q1 '25: 4.4M Q2 '25: 4.5M Q3 '25: 4.8M Q4 '25: 6M Q1 '26: 4.6M Q2 '26: 8.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow Quarterly

-30M -15M 0 15M 30M 45M Q3 '21: -10.3M Q4 '21: -19.1M Q1 '22: -25.6M Q2 '22: -12.9M Q3 '22: -13.3M Q4 '22: -21.9M Q1 '23: -4.1M Q2 '23: 5.9M Q3 '23: -1.4M Q4 '23: -6.2M Q1 '24: -5M Q2 '24: 302K Q3 '24: 21.7M Q4 '24: 14.5M Q1 '25: -893K Q2 '25: 30.5M Q3 '25: 24M Q4 '25: 22M Q1 '26: 2.7M Q2 '26: 30.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-40M -20M 0 20M 40M 60M Q1 '18: -23.6M Q2 '18: -27.7M Q3 '18: -20.2M Q4 '18: 11.6M Q1 '19: -946K Q2 '19: -16.8M Q3 '19: -15M Q4 '19: -10.3M Q1 '20: -3.7M Q2 '20: -14.1M Q3 '20: -19.7M Q4 '20: -16.1M Q1 '21: -20M Q2 '21: 54.8M Q3 '21: -10.5M Q4 '21: -19.1M Q1 '22: -25.9M Q2 '22: -12.9M Q3 '22: -13.5M Q4 '22: -22M Q2 '18 Q1 '19 Q4 '19 Q3 '20 Q2 '21 Q1 '22 Q4 '22

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 60M 120M 180M Q2 '20: 168.6M Q3 '20: 168.9M Q4 '20: 169M Q1 '21: 176.1M Q2 '21: 170.2M Q3 '21: 170.9M Q1 '22: 171.8M Q2 '22: 172.1M Q3 '22: 172.8M Q1 '23: 173.6M Q2 '23: 17.4M Q3 '23: 17.4M Q1 '24: 17.5M Q2 '24: 17.5M Q3 '24: 17.6M Q1 '25: 18.2M Q2 '25: 18.2M Q3 '25: 19.2M Q1 '26: 19.7M Q2 '26: 19.6M Q3 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-7.00 0.00 7.00 14.00 21.00 Q3 '21: -0.10 Q4 '21: -0.11 Q1 '22: -0.49 Q2 '22: -0.49 Q3 '22: -0.48 Q4 '22: -3.44 Q1 '23: -3.36 Q2 '23: -3.66 Q3 '23: -3.88 Q4 '23: -0.74 Q1 '24: -1.13 Q2 '24: -0.81 Q3 '24: 0.22 Q4 '24: 0.98 Q1 '25: 2.08 Q2 '25: 5.42 Q3 '25: 6.18 Q4 '25: 19.47 Q1 '26: 19.28 Q2 '26: 16.88 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.